A phase I dose-ranging study of the safety, tolerability, and immunogenicity of the Merck trivalent adenovirus serotype 5 HIV-1 gag/pol/nef vaccine (MRKAd5 HIV-1 gag/pol/nef) in a prime-boost regimen in healthy adults

Trial Profile

A phase I dose-ranging study of the safety, tolerability, and immunogenicity of the Merck trivalent adenovirus serotype 5 HIV-1 gag/pol/nef vaccine (MRKAd5 HIV-1 gag/pol/nef) in a prime-boost regimen in healthy adults

Not stated
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2006

At a glance

  • Drugs V 520 (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top